Development of a core outcome set and identification of patient- reportable outcomes for primary brain tumour trials: protocol for the cobra study

HIGHLIGHTS

• who: Ameeta Retzer u200d u200d and colleagues from the Primary brain tumours, specifically gliomas, are a rare disease groupThe disease and treatment negatively impacts on patients and those close to them. The high rates of physical and cognitive morbidity differ from other cancers causing reduced health-u00adrelated quality of life. Glioma trials using outcomes that allow holistic analysis of treatment benefits and risks enable informed care decisions. Currently, outcome assessment in glioma trials is inconsistent, hindering evidence synthesis. A core outcome set (COS), an agreed minimum set of outcomes to be measured and reported, may address this . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.